Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index; 13 of the 17 sources its claims cite were checked for support.

Combined Transcriptome and Metabolome Analysis Reveals That the Potent Antifungal Pyrylium Salt Inhibits Mitochondrial Complex I in Candida albicans

Open access
Lv, Quanzhen, Yan, Lan, Wang, Jinxin, Feng, Jia, Gao, Lu, Qiu, Lijuan, Chao, Wen, Qin, Yu-Lin, Jiang, Yuanying · 2023 · Microbiology Spectrum

Abstract

Transcriptome and metabolome analysis showed that the antifungal compound xy12 inhibits mitochondrial complex I in Candida albicans.

Overview

CoChat Summary

TL;DR

The pyrylium salt derivative xy12 has stronger anti-*Candida albicans* activity than SM21 and acts by inhibiting mitochondrial complex I, disrupting oxidative phosphorylation and ATP production. Integrated transcriptome and metabolome analyses plus mitochondrial mutant and biochemical assays support complex I as a key antifungal target.

Key findings

  • xy12 had MIC90 values of 0.125–0.25 μg/mL against *C. albicans* isolates, about 2-fold lower than SM21, including against fluconazole-resistant clinical isolates. It inhibited hypha formation and biofilm formation dose-dependently; 1 μg/mL inhibited about 30%–40% of biofilm, and 2 or 4 μg/mL reduced biofilm to about 15%.
  • RNA-seq identified 1,826 upregulated and 1,628 downregulated genes; metabolomics identified 1,197 metabolites and 260 differential metabolites. Integrated KEGG analysis highlighted oxidative phosphorylation and carbon-source metabolism, with downregulation of mitochondrial complex I–V genes and accumulation of TCA intermediates such as succinate and fumarate.
  • Mitochondrial complex I–deficient mutants (nue1Δ/Δ, nue2Δ/Δ, nuo3Δ/Δ, nuo4Δ/Δ) showed decreased sensitivity to 0.5 μg/mL xy12, whereas complex III– and IV–deficient mutants showed increased sensitivity. Rotenone antagonized xy12, increasing MIC90 from 0.25 to 0.5 and 1 μg/mL; carboxin was synergistic, reducing MIC90 to 0.125 or 0.0313 μg/mL.
  • xy12 reduced mitochondrial complex I activity by about 30% at 0.5 μg/mL and about 50% at 1 μg/mL, decreased intracellular ATP at 2 or 4 μg/mL, reduced mitochondrial membrane potential, caused mtDNA loss, impaired mitochondrial morphology, and decreased cell wall N-linked mannoproteins.

Methods

  • *C. albicans* SC5314, clinical isolates, and mitochondrial complex–deficient mutants were tested by MIC, disk diffusion, time-growth/time-kill, hypha, biofilm (XTT and crystal violet), spot, and checkerboard assays.
  • RNA-seq was performed on DMSO- or 2 μg/mL xy12-treated SC5314 for 3 h; DEGs were defined as P < 0.05 and |log2-fold change| ≥ 1, with GO/KEGG enrichment. Untargeted metabolomics used UHPLC-QTOF-MS after 2 μg/mL xy12 treatment for 8 h; differential metabolites were defined by OPLS-DA VIP > 1 and P < 0.05.
  • Follow-up assays included RT-qPCR, mitochondrial complex I activity measurement, ATP quantification, JC-1 mitochondrial membrane potential, MitoTracker/Tom70p-GFP microscopy, Alcian blue and ConA-FITC cell wall staining, and growth on fermentable versus nonfermentable carbon sources.

Limitations

  • The paper states that direct binding of xy12 to mitochondrial complex I was not studied in depth, and future work is needed to identify interacting subunits and NADH/coenzyme Q effects. It also states that whether xy12 affects mitochondrial fusion or division was not determined.
  • The paper notes that hypha and biofilm inhibition occurred at higher concentrations than the MIC90, so it is difficult to conclude whether those effects are due to disrupted mitochondrial function or simply inhibition of proliferation. It also notes that xy12-treated cells still grew slowly on nonfermentable carbon sources, suggesting other antifungal mechanisms are involved.
  • The paper states that HPLC-MS rather than GC-MS was used, so identified metabolites were dominated by highly polar compounds and lipid-related pathways were less enriched. The text makes evident that this study reports in vitro experiments; in vivo efficacy is cited from prior work rather than demonstrated here.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1128/spectrum.03209-22

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

FIG 1 The chemical structures and antifungal activity of compounds SM21 and xy12. (A) The chemical structures of SM21 and xy12. (B) Filter disk-diffusion assay of Candida albicans SC5314. Filter disks with 1, 2, and 4 μg fluconazole, SM21, or xy12 were placed on yeast extract-peptone-dextrose (YPD) agar and cultured at 30°C for 24 h.
FIG 1 The chemical structures and antifungal activity of compounds SM21 and xy12. (A) The chemical structures of SM21 and xy12. (B) Filter disk-diffusion assay of Candida albicans SC5314. Filter disks with 1, 2, and 4 μg fluconazole, SM21, or xy12 were placed on yeast extract-peptone-dextrose (YPD) agar and cultured at 30°C for 24 h.CC BY · PubMed Central
FIG 2 The compound xy12 inhibited growth and hypha and biofilm formation in C. albicans. (A) Time-growth curves. C. albicans SC5314 was treated with 1, 2, or 4 μg/mL of xy12 for 24 h and the OD600 (optical density at 600 nm) was measured at the indicated time points. (B) Time-kill curves of xy12 against C. albicans. C. albicans SC5314 was incubated with different concentrations of xy12 for 6 or 12 h in RPMI 1640 or YPD medium and plated on Sabouraud dextrose agar to count the living clones. (C) Hypha formation. C. albicans SC5314 was adjusted to 3 × 105 cells/mL in Spider or RPMI 1640 medium with or without the indicated concentrations of xy12 and cultured at 37°C for 3 h. (D) Biofilm formation detected by XTT [2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide] reduction. Biofilms of C. albicans SC5314 with or without xy12 treatment were induced in RPMI 1640 medium at 37°C for 24 h. XTT/menadione was added to the wells and the absorbance of supernatant was measured at 490 nm. ***, P < 0.001, unpaired t test. (E) Biofilm formation stained by crystal violet. The biofilms were stained with 0.4% crystal violet and quantified. (F) The coated cells were photographed.
FIG 2 The compound xy12 inhibited growth and hypha and biofilm formation in C. albicans. (A) Time-growth curves. C. albicans SC5314 was treated with 1, 2, or 4 μg/mL of xy12 for 24 h and the OD600 (optical density at 600 nm) was measured at the indicated time points. (B) Time-kill curves of xy12 against C. albicans. C. albicans SC5314 was incubated with different concentrations of xy12 for 6 or 12 h in RPMI 1640 or YPD medium and plated on Sabouraud dextrose agar to count the living clones. (C) Hypha formation. C. albicans SC5314 was adjusted to 3 × 105 cells/mL in Spider or RPMI 1640 medium with or without the indicated concentrations of xy12 and cultured at 37°C for 3 h. (D) Biofilm formation detected by XTT [2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide] reduction. Biofilms of C. albicans SC5314 with or without xy12 treatment were induced in RPMI 1640 medium at 37°C for 24 h. XTT/menadione was added to the wells and the absorbance of supernatant was measured at 490 nm. ***, P < 0.001, unpaired t test. (E) Biofilm formation stained by crystal violet. The biofilms were stained with 0.4% crystal violet and quantified. (F) The coated cells were photographed.CC BY · PubMed Central
FIG 3 Effect of xy12 on the transcriptome in C. albicans. (A) Principal-component analysis of RNA-seq to evaluate the correlation and dispersion between different samples. The groups of dimethyl sulfoxide (DMSO)-treated (mock) and xy12-treated (xy12) C. albicans are shown in red and blue. (B) The top 20 enriched KEGG pathways are shown. Vertical axis represents KEGG annotation, horizontal axis represents the Rich factor. (C) Heatmap of differentially expressed genes (|log2-fold change| ≥ 1, P < 0.05) involved in oxidative phosphorylation. Blue color indicates downregulated genes.
FIG 3 Effect of xy12 on the transcriptome in C. albicans. (A) Principal-component analysis of RNA-seq to evaluate the correlation and dispersion between different samples. The groups of dimethyl sulfoxide (DMSO)-treated (mock) and xy12-treated (xy12) C. albicans are shown in red and blue. (B) The top 20 enriched KEGG pathways are shown. Vertical axis represents KEGG annotation, horizontal axis represents the Rich factor. (C) Heatmap of differentially expressed genes (|log2-fold change| ≥ 1, P < 0.05) involved in oxidative phosphorylation. Blue color indicates downregulated genes.CC BY · PubMed Central
FIG 4 Metabolomics analysis of samples extracted from xy12-treated C. albicans. (A) The relationship between metabolite content and groups was analyzed by orthogonal partial least-squares discriminant analysis. Scores plot showed the groups of xy12-treated (blue) and DMSO-treated (green) C. albicans SC5314 in a negative (left) and positive (right) ion model. (B) Correlations between metabolites shown by chord diagrams. Arcs on the outer circle indicate the categories of significantly different metabolites. Colored lines indicate the correlations within the various metabolites.
FIG 4 Metabolomics analysis of samples extracted from xy12-treated C. albicans. (A) The relationship between metabolite content and groups was analyzed by orthogonal partial least-squares discriminant analysis. Scores plot showed the groups of xy12-treated (blue) and DMSO-treated (green) C. albicans SC5314 in a negative (left) and positive (right) ion model. (B) Correlations between metabolites shown by chord diagrams. Arcs on the outer circle indicate the categories of significantly different metabolites. Colored lines indicate the correlations within the various metabolites.CC BY · PubMed Central
FIG 5 Treatment with xy12 changed the metabolites in carbohydrate and energy metabolism pathways. (A) Differential abundance (DA) score analysis of metabolites. The DA score represents the total change of all metabolites in the metabolic pathway. A score of 1 indicates that all identified metabolites in the pathway were upregulated; a score of of −1 indicates that all metabolites were downregulated. Dot size represents the number of metabolites in a pathway. (B) Heat map of differential metabolites located in the carbohydrate metabolism, carbon metabolism, and pyruvate metabolism pathways. Z-score standardized peak intensity was used to portray the relative quantity and changing trend of each metabolite in heat maps by MeV software. Red indicates upregulation, blue indicates downregulation.
FIG 5 Treatment with xy12 changed the metabolites in carbohydrate and energy metabolism pathways. (A) Differential abundance (DA) score analysis of metabolites. The DA score represents the total change of all metabolites in the metabolic pathway. A score of 1 indicates that all identified metabolites in the pathway were upregulated; a score of of −1 indicates that all metabolites were downregulated. Dot size represents the number of metabolites in a pathway. (B) Heat map of differential metabolites located in the carbohydrate metabolism, carbon metabolism, and pyruvate metabolism pathways. Z-score standardized peak intensity was used to portray the relative quantity and changing trend of each metabolite in heat maps by MeV software. Red indicates upregulation, blue indicates downregulation.CC BY · PubMed Central
FIG 6 Combined analysis of the metabolome and transcriptome of C. albicans treated with xy12. Quantity and description of common enriched KEGG pathways in transcriptome and metabolome (A). Blue represents the transcriptome and orange represents the metabolome. Horizontal axis indicates the significance of enrichment (B). (C) Schematic representation of oxidative phosphorylation pathway. Green boxes represent the downregulated genes, red circles represent the upregulated metabolites.
FIG 6 Combined analysis of the metabolome and transcriptome of C. albicans treated with xy12. Quantity and description of common enriched KEGG pathways in transcriptome and metabolome (A). Blue represents the transcriptome and orange represents the metabolome. Horizontal axis indicates the significance of enrichment (B). (C) Schematic representation of oxidative phosphorylation pathway. Green boxes represent the downregulated genes, red circles represent the upregulated metabolites.CC BY · PubMed Central
FIG 7 Effects of xy12 on the mitochondrial complexes and ATP production. (A) Sensitivities of the mitochondrial complex-deficient mutants to xy12 as determined by spot assay. C. albicans mutants were spotted on YPD agar with the indicated concentrations of xy12 and cultured for 48 h. (B and C) Checkerboard assays of the antifungal activity of rotenone (B) and carboxin (C) combined with xy12 against C. albicans SC5314 for 48 h. Growth inhibition was determined by OD600. Green regions represent higher cell density. (D) Relative expression of genes encoding mitochondrial complex I determined by reverse transcription-quantitative PCR (RT-qPCR). Total RNA was extracted from C. albicans SC5314 treated with 2 μg/mL of xy12 for 3 h. The expression of each gene was normalized to ACT1 and calculated by the threshold cycle (2−ΔΔCT) method. Relative levels of mRNA represented the fold changes between the xy12-treated cells and the DMSO-treated cells (mock). The gene expression of DMSO-treated cells was normalized to 1. (E) The activity of mitochondrial complex I inhibited by xy12. Mitochondria were isolated from C. albicans SC5314 and treated with 0.25, 0.5, and 1 μg/mL of xy12 for 3 h. (F) Intracellular ATP content of C. albicans SC5314 treated with xy12 for 6 h. ATP content was measured by the Titer-Glo cell reagent. Data are shown as mean ± standard deviation. **, P < 0.01; ***, P < 0.001 by unpaired t test.
FIG 7 Effects of xy12 on the mitochondrial complexes and ATP production. (A) Sensitivities of the mitochondrial complex-deficient mutants to xy12 as determined by spot assay. C. albicans mutants were spotted on YPD agar with the indicated concentrations of xy12 and cultured for 48 h. (B and C) Checkerboard assays of the antifungal activity of rotenone (B) and carboxin (C) combined with xy12 against C. albicans SC5314 for 48 h. Growth inhibition was determined by OD600. Green regions represent higher cell density. (D) Relative expression of genes encoding mitochondrial complex I determined by reverse transcription-quantitative PCR (RT-qPCR). Total RNA was extracted from C. albicans SC5314 treated with 2 μg/mL of xy12 for 3 h. The expression of each gene was normalized to ACT1 and calculated by the threshold cycle (2−ΔΔCT) method. Relative levels of mRNA represented the fold changes between the xy12-treated cells and the DMSO-treated cells (mock). The gene expression of DMSO-treated cells was normalized to 1. (E) The activity of mitochondrial complex I inhibited by xy12. Mitochondria were isolated from C. albicans SC5314 and treated with 0.25, 0.5, and 1 μg/mL of xy12 for 3 h. (F) Intracellular ATP content of C. albicans SC5314 treated with xy12 for 6 h. ATP content was measured by the Titer-Glo cell reagent. Data are shown as mean ± standard deviation. **, P < 0.01; ***, P < 0.001 by unpaired t test.CC BY · PubMed Central
FIG 8 Abnormal mitochondrial morphology and functions caused by xy12. (A) Mitochondrial morphology of C. albicans SC5314 or Tom70p-GFP strains treated with xy12 or fluconazole (FLC) was observed. C. albicans SC5314 was stained with 100 nM MitoTracker Red CMXRos for 30 min. (B) Mitochondrial membrane potential of C. albicans SC5314 was measured by JC-1. C. albicans were stained with JC-1 buffer for 20 min and the fluorescence of JC-1 was detected at 590 nm and 530 nm. (C) Mitochondrial DNA (mtDNA) of C. albicans SC5314 was analyzed by RT-qPCR. Total DNA of C. albicans was extracted and the relative expression of mtDNA NAD5 and ATP6 was normalized to that of ACT1.
FIG 8 Abnormal mitochondrial morphology and functions caused by xy12. (A) Mitochondrial morphology of C. albicans SC5314 or Tom70p-GFP strains treated with xy12 or fluconazole (FLC) was observed. C. albicans SC5314 was stained with 100 nM MitoTracker Red CMXRos for 30 min. (B) Mitochondrial membrane potential of C. albicans SC5314 was measured by JC-1. C. albicans were stained with JC-1 buffer for 20 min and the fluorescence of JC-1 was detected at 590 nm and 530 nm. (C) Mitochondrial DNA (mtDNA) of C. albicans SC5314 was analyzed by RT-qPCR. Total DNA of C. albicans was extracted and the relative expression of mtDNA NAD5 and ATP6 was normalized to that of ACT1.CC BY · PubMed Central
FIG 9 Abnormal carbon utilization and cell wall structures caused by xy12 treatment. (A) Checkerboard assays of antifungal activity of xy12 against C. albicans SC5314 in media containing different carbon sources. After 24 h of incubation, the OD600 was used to calculate growth inhibition. Green regions indicate higher cell density. (B) The cell wall of C. albicans SC5314 was observed by transmission electron microscopy. C. albicans was treated with 2 μg/mL of xy12 for 16 h in YPD medium. Red arrows indicate the cell wall fibers. (C) Phosphomannan of C. albcians SC5314 was stained by Alcian blue. C. albicans was treated with 2 or 4 μg/mL of xy12 for 16 h in YPD medium. Data are shown as mean ± standard deviation. **, P < 0.01; ***, P < 0.001 by unpaired t test. (D) Mannan of the cell wall was stained by ConA-FITC (fluorescein isothiocyanate). C. albicans SC5314 was treated with 4 μg/mL of xy12 for 16 h in YPD medium and photographed by confocal microscopy.
FIG 9 Abnormal carbon utilization and cell wall structures caused by xy12 treatment. (A) Checkerboard assays of antifungal activity of xy12 against C. albicans SC5314 in media containing different carbon sources. After 24 h of incubation, the OD600 was used to calculate growth inhibition. Green regions indicate higher cell density. (B) The cell wall of C. albicans SC5314 was observed by transmission electron microscopy. C. albicans was treated with 2 μg/mL of xy12 for 16 h in YPD medium. Red arrows indicate the cell wall fibers. (C) Phosphomannan of C. albcians SC5314 was stained by Alcian blue. C. albicans was treated with 2 or 4 μg/mL of xy12 for 16 h in YPD medium. Data are shown as mean ± standard deviation. **, P < 0.01; ***, P < 0.001 by unpaired t test. (D) Mannan of the cell wall was stained by ConA-FITC (fluorescein isothiocyanate). C. albicans SC5314 was treated with 4 μg/mL of xy12 for 16 h in YPD medium and photographed by confocal microscopy.CC BY · PubMed Central

Verification

Claims the paper makes

10 Valid · 2 Not valid · 4 Not checked · 102 Own results and interpretations

87 more claims

Create a free account to see all 118 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 8
  • It may state two separate claims as one. 20

Create a free account to see these claims.

Citations

Cites

Show all 44 references

Metadata

Authors
Lv, Q., Yan, L., Wang, J., Feng, J., Gao, L., Qiu, L., Chao, W., Qin, Y.-L., & Jiang, Y.
Affiliations
  • Second Military Medical University (CN)
  • Tongji University (CN)
  • Fudan University Minhang Hospital, Shanghai, People’s Republic of China
Corresponding author
Jiang, Yuanying
Venue
Microbiology Spectrum
Published
2023-04-13
Volume
11
Issue
2
Pages
e0320922-e0320922
ISSN
2165-0497 (ISSN-L)
OpenAlex
W4320856057
Cited by
12
References
44
Citations by year
2026: 6 · 2025: 2 · 2024: 4
FWCI
2.33
Type
journal article
Language
en
Open access
Licence
Locations
  • Microbiology Spectrum (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • MOST | National Key Research and Development Program of China (2021YFC2300400)
  • National Natural Science Foundation of China (81902039, 82020108032, 82173867)
Topics
  • Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
  • Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
  • Life Sciences › Immunology and Microbiology › Applied Microbiology and Biotechnology › Microbial Natural Products and Biosynthesis
Keywords
Candida albicans, antifungal agents, mitochondrial complex I inhibition, transcriptome, metabolome, antifungal resistance

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Combined Transcriptome and Metabolome Analysis Reveals That the Potent Antifungal Pyrylium Salt Inhibits Mitochondrial Complex I in Candida albicans. https://app.cochat.ai/papers/10.1128/spectrum.03209-22
The paper
Lv, Q., Yan, L., Wang, J., Feng, J., Gao, L., Qiu, L., Chao, W., Qin, Y.-L., & Jiang, Y. (2023). Combined Transcriptome and Metabolome Analysis Reveals That the Potent Antifungal Pyrylium Salt Inhibits Mitochondrial Complex I in Candida albicans. Microbiology Spectrum. https://doi.org/10.1128/spectrum.03209-22

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.